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Background: Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial
growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic
colorectal cancers. With the completion of six global, randomized, double-blind, placebo-controlled, phase III trials across
multiple tumor types, an opportunity now exists to further establish the safety parameters of ramucirumab across a large
patient population.
Materials and methods: An individual patient meta-analysis across the six completed phase III trials was conducted and the
relative risk (RR) and associated 95% confidence intervals (CIs) were derived using fixed-effects or mixed-effects models for all-
grade and high-grade adverse events (AEs) possibly related to vascular endothelial growth factor pathway inhibition. The
number needed to harm was also calculable due to the placebo-controlled nature of all six registration standard trials.
Results: A total of 4996 treated patients (N¼ 2748 in the ramucirumab arm and N¼ 2248 in the control, placebo arm) were
included in this meta-analysis. Arterial thromboembolic events [ATE; all-grade, RR: 0.8, 95% CI 0.5–1.3; high-grade (grade3),
RR: 0.9, 95% CI 0.5–1.7], venous thromboembolic events (VTE; all-grade, RR: 0.7, 95% CI 0.5–1.1; high-grade, RR: 0.7, 95% CI
0.4–1.2), high-grade bleeding (RR: 1.1, 95% CI 0.8–1.5), and high-grade gastrointestinal (GI) bleeding (RR: 1.1, 95% CI 0.7–1.7)
did not demonstrate a definite increased risk with ramucirumab. A higher percentage of hypertension, proteinuria, low-grade
(grade 1–2) bleeding, GI perforation, infusion-related reaction, and wound-healing complications were observed in the
ramucirumab arm compared with the control arm.
Conclusions: Ramucirumab may be distinct among antiangiogenic agents in terms of ATE, VTE, high-grade bleeding, or
high-grade GI bleeding by showing no clear evidence for an increased risk of these AEs in this meta-analysis of a large and
diverse patient population. Ramucirumab is consistent with other angiogenic inhibitors in the risk of developing certain AEs.
Clinical Trial Numbers: NCT00917384 (REGARD), NCT01170663 (RAINBOW), NCT01168973 (REVEL), NCT01183780 (RAISE),
NCT01140347 (REACH), and NCT00703326 (ROSE).
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Introduction
Ramucirumab (CYRAMZA
VR
, Eli Lilly and Company,
Indianapolis, IN, USA) is a fully human immunoglobulin G1
monoclonal antibody with high affinity binding to the vascular
endothelial growth factor receptor 2 (VEGFR-2) extracellular do-
main, blocking binding of multiple VEGF ligands and receptor
activation. Ramucirumab has received approval for second-line
therapy in gastric, lung, and colorectal cancers [1, 2].
Risk–benefit assessment is an important component of phys-
ician and patient decision making in selecting cancer treatments.
The need to minimize treatment-related toxicity while maximiz-
ing efficacy is paramount. To date, the results of six global,
randomized, double-blind, placebo-controlled, phase III clinical
trials with different tumor types have been published to present
the efficacy and safety profile of ramucirumab [3–9] (Table 1).
The purpose of this report is to (i) examine the incidence of ad-
verse events possibly attributed to VEGF pathway inhibition based
on data from six phase III clinical trials, (ii) determine specific pa-
tient- and treatment-related factors that may be associated with an
increased adverse event risk, and (iii) explore how specific
observed adverse events may be managed in the clinical setting.
Pooled data from these trials provide an opportunity to evalu-
ate relatively infrequent adverse events at the individual patient
level. While conditions such as thrombosis and bowel perforation
may occur as part of the natural history of advanced cancers,
using only registration standard placebo-controlled trials in eval-
uating reported adverse events permits an unbiased estimate of
the number needed to trigger one additional adverse event com-
pared with the control arm [the number needed to harm
(NNH)], whereas uncontrolled trials coalesce causation and nat-
ural history.
Methods of analysis
A meta-analysis was conducted to review reported adverse
events across the six completed phase III ramucirumab trials.
An overview of the trials and all randomized patients (intent-
to-treat population) is provided in Table 1, with the data based
on the primary database lock for each trial. As all studies were
placebo-controlled, the term ‘control arm’ is used herein to
pool studies with placebo and those with chemotherapy plus
placebo. Adverse events possibly attributed to VEGF inhib-
ition, based on literature review [10], were evaluated in pa-
tients receiving at least one dose of study drug (safety
population). Consolidated adverse event terms are defined in
Table 1. Ramucirumab double-blind randomized controlled phase III clinical trials
Trial Indication Treatment arms Patients
randomized
per arma
Date first patient
enrolled
NCI CTCAE Trial
registry
number
REGARDb [3] Advanced gastric
or GEJ adenocarcinoma
Ramucirumab 8mg/kg i.v. Q2W plus
BSC or placebo plus BSC
RAM: n ¼ 238 6 October 2009 v4.02 NCT00917384
I4T-IE-JVBD Control: n ¼ 117
RAINBOWb [4]
I4T-IE-JVBE
Advanced gastric
or GEJ adenocarcinoma
Ramucirumab 8mg/kg i.v. on days
1 and 15, plus paclitaxel 80mg/m2
i.v. on days 1, 8, and 15 of a 28-day
cycle or placebo i.v. plus paclitaxel
80mg/m2 i.v. on days 1, 8, and 15
of a 28-day cycle
RAM: n ¼ 330
Control: n ¼ 335
23 December 2010 v4.02 NCT01170663
REVELb [5] Stage IV NSCLC Ramucirumab 10mg/kg i.v. plus
docetaxel 75mg/m2 on day 1 of a
21-day cycle or placebo plus
docetaxel 75mg/m2 on day 1 of a
21-day cycle
RAM: n ¼ 628 03 December 2010 v4.0 NCT01168973
I4T-MC-JVBA Control: n ¼ 625
RAISEb [6] Metastatic CRC Ramucirumab 8mg/kg i.v. plus
FOLFIRI Q2W or placebo plus
FOLFIRI Q2W
RAM: n ¼ 536 13 December 2010 v4.02 NCT01183780
I4T-MC-JVBB Control: n ¼ 536
REACHb [7] Advanced HCC Ramucirumab 8mg/kg i.v. Q2W plus
BSC or placebo Q2W plus BSC
RAM: n ¼ 283 04 November 2010 v4.0 NCT01140347
I4T-IE-JVBF Control: n ¼ 282
ROSEc [8] Metastatic breast cancer Ramucirumab 10mg/kg i.v. plus
docetaxel 75mg/m2 Q3W or doce-
taxel 75mg/m2 plus placebo Q3W
RAM: n ¼ 759 11 August 2008 v3.0 NCT00703326
I4T-IE-JVBC Control: n ¼ 385
aIntent-to-treat population.
bThe primary end point for these studies was overall survival.
cThe primary end point for this study was progression-free survival.
BSC, best supportive care; CRC, colorectal carcinoma; GEJ, gastroesophageal junction; FOLFIRI, leucovorin (folinic acid), ﬂuorouracil, and irinotecan; HCC,
hepatocellular carcinoma; i.v., intravenous; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; NSCLC, non-small-cell
lung cancer; Q2W, every two weeks; Q3W, every 3weeks; RAM, ramucirumab; v, version.
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the supplementary Appendix, available at Annals of Oncology
online. Although only arterial thromboembolic events (ATE)
are considered associated with the antiangiogenic class [10],
venous thromboembolic events (VTE) are also reported along
with ATE, but the association between antiangiogenic agents
and VTE remains unclear [11–14]. Grading of the adverse
events was based on Common Terminology Criteria for
Adverse Events, versions 3.0–4.02.
The relative risk (RR) and the associated 95% confidence
interval (CI) were calculated for all-grade and severe/high-
grade (grade 3) adverse events. The overall RR and 95% CI
were derived using fixed-effects or mixed-effects models.
In addition, for rare, severe, and fatal events, a simple pooled
result or absolute risk difference without adjustment is pre-
sented. To determine consistency among studies, the meta-
analyses included a statistical test of heterogeneity to determine
whether any differences in RR of an adverse event were due
to chance or actual differences in study results. The assumption
of homogeneity was considered rejected for P < 0.10 from
Cochran’s Q test. RRs were derived using a random-effects
model only if the significant heterogeneity was identified among
studies. Otherwise, a fixed-effects model based on the inverse
variance weighting of the selected studies was used to pool the
RR. The NNH and NNH leading to discontinuation were
derived by calculating the inverse of the attributable risk: specif-
ically, 1/(experimental rate control rate). When the calculated
NNH numerical value in a given section is a negative number,
due to the incidence being lower in ramucirumab than in
the control arm, such values are reported in data tables and not
in the Results section. The statistical analysis was carried out in
R3.1.1 [R Core Team (2016)] [15].
Results
A total of 4996 randomized patients received at least one dose of
the study drug (safety population of 2748 received ramucirumab
and 2248 received placebo). Patient characteristics and demo-
graphics are presented in Table 2, with the ramucirumab expos-
ure being presented in the supplementary Table S1, available at
Annals of Oncology online. Major inclusion criteria for study en-
rollment, such as adequate hematologic, hepatic, coagulation,
and renal function at baseline, were similar across all trials.
The following sections focus on some specific adverse events
reported in these six randomized trials.
Hypertension
Arterial hypertension was defined as either new onset or a worsening
grade of pre-existing hypertension during the trial. As shown in Table
3, there were 585 (21.3%) and 167 (7.4%) patients with all-grade
hypertension in the ramucirumab and control arms, respectively. The
corresponding RR was 2.7 (95% CI 2.3–3.2). A total of 246 (9.0%) pa-
tients in the ramucirumab arm experienced grade 3 hypertension
compared with 57 (2.5%) in the control arm (RR: 3.7, 95% CI 2.8–
4.9). This 6.5% increase for grade3 hypertension in the ramuciru-
mab arm represents an NNH of 1 in 16 patients (Table 4). There were
only two (0.07%) reported instances of grade 4 hypertensive crisis in
the ramucirumab arm (zero in control) among these trials. There
were no deaths due to hypertension. In most cases, hypertension was
controlled using standard antihypertensive treatment, while patients
continued to receive ramucirumab therapy. Only 0.3% of patients (8/
2748) discontinued ramucirumab treatment due to hypertension, or
1 in 344 patients who started ramucirumab [16].
Table 2. Patient characteristics in the intent-to-treat population of ramucirumab double-blind randomized controlled phase III clinical trials
REGARD RAINBOW REVEL RAISE REACH ROSE
RAM
n5 238
Control
n5117
RAM
n5 330
Control
n5 335
RAM
n5 628
Control
n5625
RAM
n5536
Control
n5 536
RAM
n5 283
Control
n5 282
RAM
n5759
Control
n5385
Median age,
years (range)
60 (30–86) 60 (24–87) 61 (25–83) 61 (24–84) 62 (21–85) 61 (25–86) 62 (21–83) 62 (33–87) 64 (28–87) 62 (25–85) 54 (24–82) 54 (29–81)
<65, n (%) 156 (66) 71 (61) 204 (62) 212 (63) 391 (62) 407 (65) 324 (60) 321 (60) 150 (53) 162 (57) 629 (83) 325 (84)
65, n (%) 82 (34) 46 (39) 126 (38) 123 (37) 237 (38) 218 (35) 212 (40) 215 (40) 133 (47) 120 (43) 130 (17) 60 (16)
Gender, n (%)
Male 169 (71) 79 (68) 229 (69) 243 (73) 419 (67) 415 (66) 289 (54) 326 (61) 236 (83) 242 (86) 0 (0) 0 (0)
Female 69 (29) 38 (32) 101 (31) 92 (27) 209 (33) 210 (34) 247 (46) 210 (39) 47 (17) 40 (14) 759 (100) 385 (100)
Race, n (%)
White 181 (76) 91 (78) 208 (63) 199 (59) 526 (84) 503 (80) 405 (76) 410 (76) 139 (49) 137 (49) 676 (89) 341 (89)
Asian 39 (16) 17 (15) 110 (33) 121 (36) 74 (12) 86 (14) 111 (21) 103 (19) 131 (46) 135 (48) 31 (4) 20 (5)
Black 4 (2) 2 (2) 6 (2) 6 (2) 17 (3) 16 (3) 14 (3) 16 (3) 5 (2) 3 (1) 27 (4) 14 (4)
Other 14 (6) 7 (6) 6 (2) 9 (3) 10 (2) 20 (3) 4 (1) 2 (<1) 8 (3) 7 (3) 25 (3) 10 (3)
Not reported/
missing
0 (0) 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 2 (<1) 5 (1) 0 (0) 0 (0) 0 (0) 0 (0)
ECOG PS, n (%)
0 67 (28) 31 (26) 117 (35) 144 (43) 207 (33) 199 (32) 263 (49) 259 (48) 159 (56) 153 (54) 439 (58) 240 (62)
1 171 (72) 85 (73) 213 (65) 191 (57) 420 (67) 425 (68) 268 (50) 273 (51) 124 (44) 129 (46) 318 (42) 143 (37)
2 or 3 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1) 2 (<1) 0 (0) 0 (0) 2 (<1) 2 (<1)
Missing 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1) 1 (<1) 4 (1) 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0)
ECOG PS, Eastern Cooperative Oncology Group Performance Status; RAM, ramucirumab.
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Similar proportions of patients in both treatment arms
received antihypertensive agents as concurrent therapy (Table 5),
except in RAINBOW where the ramucirumab arm was 17%
higher than the control arm, possibly due to a higher rate of
hypertension in this trial.
Proteinuria
There were 259 (9.4%) patients experiencing any-grade protein-
uria in the ramucirumab arm and 70 (3.1%) patients in the
control arm (RR: 3.4, 95% CI 2.6–4.3) (Table 3). Thirty-one
(1.1%) patients in the ramucirumab arm experienced grade 3
proteinuria (including only one grade 4 and no grade 5 events)
versus one (0.04%) patient in the control arm. The NNH for
grade3 proteinuria was 1 in 92 patients (Table 4). Twenty-
seven (1.0%) patients in the ramucirumab arm and one (0.04%)
patient in the control arm discontinued investigational drug due
to proteinuria. The NNH for proteinuria leading to discontinu-
ation was 1 in 107 patients. Three patients (0.1%) with nephrotic
syndrome, exclusively from the RAISE trial, were identified in the
Table 3. Summary of the incidence and relative risk of adverse events across the six completed phase III ramucirumab clinical trials
HTN, n (%) Proteinuria, n (%) Bleeding, n (%) GI bleeding, n (%)
Safety population All grade Grade3 All grade Grade3 All grade Grade3 All grade Grade3
RAM N ¼ 2748 585 (21.3) 246 (9.0) 259 (9.4) 31 (1.1) 1031 (37.5) 74 (2.7) 186 (6.8) 45 (1.6)
Control N ¼ 2248 167 (7.4) 57 (2.5) 70 (3.1) 1 (0.04)a 426 (19.0) 62 (2.8) 103 (4.6) 36 (1.6)
Relative risk
(95% CI)
2.7 (2.3–3.2) 3.7 (2.8–4.9) 3.4 (2.6–4.3) 8.3 (2.9–24.1) 2.0 (1.8–2.2) 1.1 (0.8–1.5) 1.6 (1.3–2.0) 1.1 (0.7–1.7)
GI perforation, n (%) ATE, n (%) VTEb, n (%) IRR, n (%) Wound-healing
complications, n (%)
All grade Grade3 All grade Grade3 All grade Grade3 All gradeb Grade3 All grade Grade3
RAM 30 (1.1) 28 (1.0) 38 (1.4) 21 (0.8) 106 (3.9) 56 (2.0) 180 (6.6) 28 (1.0) 14 (0.5) 5 (0.2)
Control 7 (0.3) 6 (0.3) 40 (1.8) 19 (0.8) 116 (5.2) 61 (2.7) 104 (4.6) 13 (0.6) 4 (0.2) 0 (0)a
Relative risk
(95% CI)
3.2 (1.5–7.0) 3.2 (1.4–7.3) 0.8 (0.5–1.3) 0.9 (0.5–1.7) 0.7 (0.5–1.1) 0.7 (0.4–1.2) 1.4 (0.8–2.3) 1.5 (0.8–2.7) 2.0 (0.8–5.1) 1.9 (0.5–7.5)
aFor rare events (events that were not observed in at least one treatment arm in any study), the relative risk might not be reliable due to large variability.
bRandom-effects analysis model utilized due to signiﬁcant identiﬁed heterogeneity.
ATE, arterial thromboembolic events; CI, conﬁdence interval; GI, gastrointestinal; HTN, hypertension; IRR, infusion-related reactions; RAM, ramucirumab; VTE,
venous thromboembolic events.
Table 4. The NNH in each adverse event from the six completed phase III ramucirumab clinical trials
SUMMARY REGARD RAINBOW REVEL RAISE REACH ROSE
Safety RAM Control RAM Control RAM Control RAM Control RAM Control RAM Control RAM Control
population N52748 N5 2248 n5 236 n5 115 n5327 n5 329 n5627 n5 618 n5529 n5 528 n5 277 n5276 n5 752 n5382
NNH NNH NNH NNH NNH NNH NNH
All
grade
Grade3 All
grade
Grade3 All
grade
Grade3 All
grade
Grade3 All
grade
Grade3 All
grade
Grade3 All
grade
Grade3
Hypertension 7 16 12 20 5 8 17 29 6 12 8 11 6 20
Proteinuria 16 92 280 236 9 82 39 627 8 35 8 46 27 251
Bleeding 5 1535 71 128 4 54 7 788 5 133 8 68 4 111
GI bleeding 46 2768 372 280 25 47 91 318 18 133 145 46 44 153
GI perforation 128 133 4523 4523 109 82 158 211 88 88 N/C N/C 84 94
ATE 252 1235 59 79 317 17 931 197 296 105 263 138 276 408 248
VTE 77 148 32 33 67 111 31 86 53 48 140 138 56 55
IRR 52 227 76 N/C 46 164 116 666 35 265 15 92 1217 3420
Wound healing 302 550 N/C N/C N/C N/C 309 N/C 106 529 276 N/C 94 188
NNH calculated via the following formula: 1/(ramucirumab rate  control rate). Negative values indicate that the incidence of the given adverse event was
higher in the control than in the ramucirumab arm.
ATE, arterial thromboembolic events; GI, gastrointestinal; IRR, infusion-related reactions; N/C, not calculable; NNH, number needed to harm; RAM, ramuciru-
mab; VTE, venous thromboembolic events.
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ramucirumab arm, all of whom were Asian patients with pre-
existing hypertension treated with at least two antihypertensive
medications.
Hemorrhage/bleeding
Bleeding (all grades) was reported in 1031 (37.5%) and 426
(19.0%) patients in the ramucirumab and control arms, respect-
ively (Table 3, Figure 1) (RR: 2.0, 95% CI 1.8–2.2). Low-grade
(grade 1–2) epistaxis was the most frequently reported bleeding
event in the ramucirumab arm [ranging from 5% (REGARD) to
40% (ROSE)], with the exception of three grade 3 events. Grade
3 bleeding was reported in 74 (2.7%) patients in the ramuciru-
mab arm and 62 (2.8%) patients in the control arm (RR: 1.1, 95%
CI 0.8–1.5).
Gastrointestinal (GI) bleeding of any grade was reported in 186
(6.8%) patients in the ramucirumab arm versus 103 (4.6%) in
the control arm (RR: 1.6, 95% CI 1.3–2.0) (Table 3). Grade 3
events were infrequent and occurred at the same rate (1.6%) in
both treatment groups (RR: 1.1, 95% CI 0.7–1.7). Thus, no differ-
ence was observed for high-grade (grade3) bleeding/GI bleed-
ing between the ramucirumab and control arms.
There were six (0.2%) patients in the ramucirumab arm who
experienced grade 4 bleeding events and four of them were GI
bleeding events. Ten (0.4%) patients in the control arm experi-
enced grade 4 bleeding events, and four of them were GI bleeding
events. Fatal hemorrhage/bleeding events were reported in 17
(0.6%) patients in the ramucirumab arm: GI bleeding (n¼ 9),
pulmonary hemorrhage (n¼ 6), hepatic hemorrhage (n¼ 1),
and hemorrhagic shock (n¼ 1). There were 14 (0.6%) fatal hem-
orrhage/bleeding events in the control arm: GI bleeding (n¼ 5),
pulmonary hemorrhage (n¼ 6), intracranial hemorrhage
(n¼ 2), and aortic aneurysm rupture (n¼ 1). Twenty-five pa-
tients (0.9%) discontinued ramucirumab treatment due to
bleeding/hemorrhage [GI bleeding (n¼ 15), intracranial hemor-
rhage (n¼ 3), epistaxis (n¼ 3), hepatic hemorrhage (n¼ 2),
hematuria (n¼ 1), and hemoptysis (n¼ 1)] compared with 17
patients (0.8%) discontinuing placebo treatment [GI bleeding
(n¼ 14), hepatic hemorrhage (n¼ 1), menorrhagia (n¼ 1), and
hemorrhage in unknown location (n¼ 1)]. The discontinuation
rate was low and similar between the two arms.
As pulmonary hemorrhage has been a concern for non-small-
cell lung cancer (NSCLC) patients treated with antiangiogenic
agents [17], we compared the incidence of all-grade pulmonary
hemorrhage in both squamous and nonsquamous NSCLC histol-
ogies in the REVEL trial and showed it to be similar between the
treatment arms (squamous: ramucirumab arm all-grade¼ 9.6%,
high-grade¼ 1.9%; control arm all-grade¼ 12.4%, high-grade¼
2.4%; nonsquamous: ramucirumab arm all-grade ¼ 7.3%, high-
grade¼ 1.1%; control arm all-grade¼ 5.7%, high-grade¼ 0.9%)
[5].
GI perforation
There were 30 (1.1%) patients who experienced all-grade GI per-
foration in the ramucirumab arm and 7 (0.3%) patients in the
control arm (RR: 3.2, 95% CI 1.5–7.0) (Table 3). Grade 3 GI
perforation was reported in 28 (1.0%) patients in the ramuciru-
mab arm versus 6 (0.3%) patients in the control arm (RR: 3.2,
95% CI 1.4–7.3). Ten (0.4%) patients in the ramucirumab arm
experienced grade 4 GI perforation compared with three (0.1%)
patients in the control arm. Seven (0.3%) patients in the ramucir-
umab arm and one (0.04%) patient in the control arm experi-
enced grade 5 GI perforation. Thus, one additional grade3 GI
perforation event would occur in every 133 patients treated with
ramucirumab (Table 4). The fatal GI perforation rate in the
ramucirumab arm was 1 in 393 treated patients, compared with 1
in 2248 in the control arm. This implies an increased absolute
risk of fatal GI perforation events of approximately 1 in 476 pa-
tients treated with ramucirumab.
Arterial thromboembolic events
Overall, there were 38 (1.4%) and 40 (1.8%) cases of all-grade
ATE in the ramucirumab and control arms, respectively (RR: 0.8,
95% CI 0.5–1.3) (Table 3, Figure 1). A total of 21 (0.8%) patients
in the ramucirumab arm experienced grade 3 ATE versus 19
(0.8%) patients in the control arm (RR: 0.9, 95% CI 0.5–1.7).
Across all trials, seven (0.3%) grade 4 events were reported in
the ramucirumab arm, with four of these events not recovered or
resolved, whereas four grade 4 events were reported in the control
arm. Seven grade 5 ATE events were reported in the ramuciru-
mab arm (six myocardial events and one cerebrovascular event)
and 10 grade 5 ATE events were reported in the control arm
(seven myocardial events and three cerebrovascular events).
Overall, the mortality rate for ATE was low and similar between
the ramucirumab (0.3%) and control arms (0.4%).
Venous thromboembolic events
VTEs presented here include both symptomatic and non-
symptomatic VTE events. Overall, 106 (3.9%) patients with all-
grade VTEs were reported in the ramucirumab arm versus 116
(5.2%) in the control arm (RR: 0.7, 95% CI 0.5–1.1) (Table 3,
Table 5. Antihypertensive agents used in the completed phase III ramucir-
umab clinical trials
Patients receiving concurrent
antihypertensive therapiesa,b
RAM, n (%) Control, n (%)
REGARD 101 (42.8) 46 (40.0)
RAINBOW 180 (55.0) 124 (37.7)
REVEL 159 (25.4) 109 (17.6)
RAISE 329 (62.2) 286 (54.2)
REACH 223 (80.5) 201 (72.8)
ROSE 379 (50.4) 167 (43.7)
Patient is only counted once for each category.
aConcurrent antihypertensive therapy includes any antihypertensive ther-
apy received between treatment start date and 30 days after treatment
end, including therapies that may have started before treatment start
date.
bAntihypertensive therapies included diuretics, peripheral vasodilators,
beta-blocking agents, calcium channel antagonists, renin angiotensin
agents, and other antihypertensive therapy.
RAM, ramucirumab.
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Figure 1). Fifty-six (2.0%) patients with grade 3 VTEs were re-
ported in the ramucirumab arm and 61 (2.7%) patients in the
control arm (RR: 0.7, 95% CI 0.4–1.2).
Across all trials, 11 (0.4%) grade 4 VTEs were reported in the
ramucirumab arm and 11 (0.5%) grade 4 VTEs were reported in
the control arm. There were three grade 5 VTEs in the ramuciru-
mab arm and six in the control arm; all grade 5 VTEs in both arms
were pulmonary embolism (PE). The fatal VTE rate was low and
similar in both the ramucirumab (0.1%) and control arms (0.3%).
Ten (0.4%) patients discontinued ramucirumab treatment due to
REGARD
Ramucirumab arms Control arms
(n/events) (n/events)
All grade
ATE
All grade
VTE
Grade ≥3
236/4 115/0
RR[95% CI)
4.4(0.2,81.1)
1.2(0.4,3.9)
0.8(0.3,1.7)
0.6(0.3,1.5)
0.5(0.1,2.7)
0.8(0.3,2.5)
0.8(0.5,1.3)
3.4(0.2,65.8)
1(0.2,4.9)
0.7(0.3,2.1)
0.7(0.2,2.3)
0.3(0,8.1)
2.5(0.3,21.7)
0.9(0.5,1.7)
0.5(0.2,1.4)
0.7(0.4,1.5)
0.4(0.2,0.8)
1.3(0.8,2)
1.5(0.4,5.2)
0.6(0.3,1.1)
0.7(0.5,1.1)
RR(95% CI)
RR(95% CI)
329/5
618/13
528/13
276/4
382/5
327/6
627/10
529/8
277/2
752/8
2748/38
236/3
327/3
627/6
529/4
277/0
752/5
236/9 115/8
329/18
618/36
528/34
276/4
382/16
2248/116
327/13
627/16
529/44
277/6
752/18
115/0
329/3
618/8
528/6
276/1
382/1
2248/40
RAINBOW
REVEL
RAISE
REACH
ROSE
Summary
2748/21
2748/106
2248/19Summary
Summary
REGARD
RAINBOW
REVEL
RAISE
REACH
ROSE
REGARD
RAINBOW
REVEL
RAISE
REACH
ROSE
0.1 0.2 0.4 0.8 1.6 3 7 10 20
0.1 0.2 0.4 0.8 1.6 3 7 10 20
0.1
Favors ramucirumab Relative Risk Favors control
0.2 0.4 0.8 1.6 3 7 10 20
Grade ≥3
0.3(0.1,1.2)
0.7(0.3,1.8)
0.6(0.3,1.3)
2(1,4.1)
0.5(0.1,2.7)
0.4(0.2,1)
0.7(0.4,1.2)
RR(95% CI)
2748/56
236/3 115/5
329/11
618/18
528/11
276/4
382/12
2248/61
327/8
627/11
529/22
277/2
752/10
Summary
REGARD
RAINBOW
REVEL
RAISE
REACH
ROSE
0.1 0.2 0.4 0.8 1.6 3 7 10 20
Relative Risk
Favors
ramucirumab
Favors
control
Figure 1. Forest plots of the incidence and relative risk of ATE, VTE, and bleeding adverse events in completed phase III ramucirumab clinical
trials. ATE, arterial thromboembolic events; CI, conﬁdence interval; VTE, venous thromboembolic events; RR, relative risk.
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VTEs and 15 (0.7%) patients discontinued treatment in the control
arm, primarily due to deep vein thrombosis or PE.
Infusion-related reactions
Any-grade infusion-related reactions (IRR) was reported in 180
(6.6%) patients in the ramucirumab arm compared with 104
(4.6%) patients in the control arm (RR: 1.4, 95% CI 0.8–2.3) (Table
3). The NNH for all-grade IRR was 1 in 52 and for grade3 was 1
in 227 patients (Table 4). A total of 28 (1.0%) patients in the ramu-
cirumab arm experienced grade 3 IRR versus 13 (0.6%) in the
control arm (RR: 1.5, 95% CI 0.8–2.7). Four (0.1%) grade 4 events
were reported in the ramucirumab arm and two (0.1%) in the con-
trol arm, with the outcome in the ramucirumab arm being either
recovered or resolved. There were no grade 5 IRR reported in these
trials. Twelve patients (0.4%) in the ramucirumab arm discontin-
ued ramucirumab, whereas three (0.1%) patients in the control
arm discontinued placebo due to an IRR. The NNH for IRR leading
to discontinuation was 1 in 330 patients treated with ramucirumab.
Reversible posterior leukoencephalopathy
syndrome
Reversible posterior leukoencephalopathy syndrome (RPLS) was
reported in two (0.04%) patients in these trials, one grade 2 RPLS
in ramucirumab arm and one grade 2 RPLS in control arm, both
in the RAISE trial. Both patients’ RPLS status was confirmed with
magnetic resonance imaging. Therefore, the incidence was ap-
proximately 1 in 2700 ramucirumab-treated patients.
Wound-healing complications
All-grade wound-healing complications were reported in 14
(0.5%) patients in the ramucirumab arm, occurring only in the
RAISE (n¼ 6) and ROSE (n¼ 8) trials (Table 3 and supplemen
tary Table S2, available at Annals of Oncology online), and in 4
(0.2%) patients in the control arm (RR: 2.0, 95% CI 0.8–5.1).
Five (0.2%) patients in the ramucirumab arm experienced grade
3 wound-healing complications with zero patients in the con-
trol arm. The NNH for all-grade and grade3 wound-healing
complication events was 1 in 302 and 1 in 550 patients in the
ramucirumab and control arms, respectively (Table 4).
Discussion and clinical implications
This meta-analysis represents one of the largest individual patient
meta-analyses of an antiangiogenic drug and has some notable
findings. First, similar to the published safety data for other anti-
angiogenics as a ‘class effect’, we observed a higher percentage of
low-grade bleeding, GI perforation, wound-healing complica-
tions, hypertension, and proteinuria in the ramucirumab arm
compared with the control arm. The rates and severity of these
events are consistent with those seen in other antiangiogenic trials
[10, 18–20]. In addition, the safety profile described here is con-
sistent with the ramucirumab labels [1, 2].
Ramucirumab may differ from other antiangiogenics in rela-
tion to bleeding and thromboembolism, as no evidence for
increased risk of ATE, VTE, high-grade bleeding, or high-grade
GI bleeding was found in this meta-analysis. The lack of an
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increased risk of ATE, VTE, or high-grade bleeding differs from
published studies with other antiangiogenics [11, 12, 21–25]. The
mechanisms underlying these differences remain unclear, al-
though it cannot be ruled out that differences in the incidence of
these adverse events between ramucirumab and other antiangio-
genics may be related to differences in the patient populations.
Arterial hypertension is recognized as a common adverse
event associated with antiangiogenic therapies [26, 27]. The
mechanisms of hypertension associated with VEGF inhibition
are thought to include decreased production of nitric oxide in the
wall of arterioles and other resistance vessels [28], increased acti-
vation of the endothelin-1 system [30], and/or capillary rarefac-
tion [29]. Once detected, hypertension is readily managed with
antihypertensives and rarely delays or stops cancer treatment.
Preexisting hypertension should be controlled before starting
ramucirumab treatment, and monitoring of blood pressure is
recommended during therapy [1]. Although hypertension was
common and required treatment, only 1 out of 344 ramucirumab
patients in these trials discontinued therapy due to hypertension.
Proteinuria has been reported with antiangiogenic agents that
block the effects of VEGF-A [31–33]; however, the underlying
mechanism is not well understood. Inhibition of VEGF-
dependent interactions between podocytes and glomerular endo-
thelial cells lessens the integrity of the filtration barrier, leading to
proteinuria [34–36]. Most patients enrolled in our trials had ad-
equate renal function at baseline, and the incidence of high-grade
proteinuria in the ramucirumab arm was 1.1% (RR: 8.3, 95% CI
2.9–24.1) (Table 3). During ramucirumab therapy, the clinician
should monitor for the development or worsening of proteinuria
[1]. In most cases, proteinuria was manageable during ramuciru-
mab therapy. Only three (0.1%) patients in the ramucirumab
arm reported nephrotic syndrome.
A meta-analysis of patients from 16 randomized trials with
bevacizumab reported a proteinuria incidence of 2.2% and a sig-
nificantly increased risk for high-grade proteinuria (RR: 4.79,
95% CI 2.71–8.46; P< 0.001) [32]. This same study also reported
a 0.8% incidence of patients with nephrotic syndrome as well as
an RR of 7.78 (95% CI 1.80–33.62; P¼ 0.006] [32].
The pathogenesis of antiangiogenic-associated bleeding is not
well understood. Tumor-infiltrated vascular walls or injured mu-
cosal membranes, which exhibit high VEGF dependence, may
have an enhanced propensity to bleed [37]. Preclinical data dem-
onstrate that capillaries with endothelial fenestrations are depend-
ent on VEGF signaling [34, 38]. Thus, tumors with fenestrated
capillaries, such as those arising in endocrine glands or the GI tract,
may be particularly sensitive to anti-VEGF pathway agents, and
more likely to develop capillary damage leading to hemorrhage.
Overall, the incidence rate of all-grade bleeding and GI bleed-
ing events with ramucirumab was higher than the control arm.
However, 72% of bleeding events (739/1031) in the ramucirumab
arm were low-grade epistaxis requiring no intervention. Most
importantly, the incidence rates of severe bleeding and GI bleed-
ing (grade  3) were low and similar between the two treatment
arms. Results from the REVEL NSCLC trial also demonstrated
that, despite higher rates of all-grade pulmonary hemorrhage in
both treatment arms in squamous histology patients (9.6%
ramucirumab arm, 12.4% control arm) compared with nonsqua-
mous histology (7.3% ramucirumab arm, 5.7% control arm), the
incidence rate of pulmonary hemorrhage was similar between the
two treatment arms within each histology [5].
GI perforation is a rare but serious adverse event and can be
fatal due to severe peritonitis [19, 39]. Patients receiving ramucir-
umab in these studies had a low (1.0%) incidence of grade3 GI
perforation with an increased absolute risk of 0.7%. Despite this
low incidence, patients and physicians should be aware of GI per-
foration and consider this in the differential diagnosis of patients
with unexplained abdominal symptoms.
ATEs have been associated with some antiangiogenic thera-
peutic agents, particularly in the context of combination regi-
mens including anti-VEGF antibodies and cytotoxic
chemotherapy. Scappaticci et al. [12] reported that the risk of
ATE was increased with chemotherapy plus bevacizumab versus
chemotherapy alone (hazard ratio¼ 2.0, 95% CI 1.05–3.75,
P¼ 0.031). Cancer patients have an intrinsically increased risk
for thrombosis [23, 40]. The prevention and treatment of
thromboembolic events is important, because they are the second
most frequent cause of death in cancer patients [41]. The RRs
from our results were 0.8 (95% CI 0.5–1.3) for all-grade ATEs
and 0.9 (95% CI 0.5–1.7) for grade3 ATEs. We cannot rule out
whether the patient population included in our trials was better
selected to reduce ATE risk factors due to prior knowledge of the
potential risks for arterial embolic events. Since patients with any
ATE (including myocardial infarction, unstable angina, cerebro-
vascular accident, or transient ischemic attack) within 6–
12 months prior to randomization were excluded in all trials re-
ported here except ROSE, the risk of developing ramucirumab-
associated ATE for the patients with a recent history of ATE re-
mains unclear. In aggregate, our data suggest that ramucirumab
does not increase the risk of developing ATE.
Venous thrombosis is a common complication in patients with
cancer [42, 43]. Compared with patients without cancer, throm-
bosis in patients with cancer is significantly more likely to be fatal
[44]. Cancer patients with active malignancy have a four- to
seven-fold higher incidence of symptomatic VTE than the general
population [42, 45, 46]. VTEs have been reported with antiangio-
genic therapies [11, 23–25, 47, 48], but this association is still
controversial [11–14]. Our data demonstrated that ramucirumab
did not increase the risk of VTE compared with the control arm
(Table 3) (all-grade RR: 0.7, 95% CI 0.5–1.1; high-grade RR: 0.7,
95% CI 0.4–1.2).
Monoclonal antibodies may cause IRR [49, 50]. The incidence
of all-grade and high-grade IRR was low for both treatment
groups across these six trials (Tables 3 and 4), with the outcome
of most reported IRR being either recovered or resolved, and no
fatal IRR events were observed.
Despite previous reports of RPLS associated with antiangio-
genic drug therapy [51, 52], in this meta-analysis there were sin-
gle events in both treatment and control populations. Due to the
extreme rarity of RPLS, a much larger patient population will be
needed in order to further define this risk. Based on the evidence
to date, it remains uncertain whether ramucirumab contributes
to RPLS development.
VEGF mediates three effects for wound healing: vasodilation
to facilitate nutrient delivery and waste removal, increased vascu-
lar permeability for fibrinogen and plasminogen extravasation (pro-
viding a substrate for tissue growth), and angiogenesis for tissue
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formation and remodeling [53]. Clinical data on the effect of angio-
genesis inhibitors on wound healing are limited. The risk of develop-
ing wound-healing complications with bevacizumab has been
reported by Scappaticci et al. [54]. Patients experiencing major sur-
gery concurrent with bevacizumab treatment demonstrated
increased wound-healing complications, whereas no increased risk
of wound-healing complications was observed in those given 5-fluo-
rouracil/leucovorin-based chemotherapy plus bevacizumab 28–
60 days post-surgical intervention versus chemotherapy-only treat-
ment [54]. In the current study, the rate of the wound-healing com-
plications was low overall in the ramucirumab arm (all-grade 0.5%).
A strength of this meta-analysis is that it represents one of the
largest meta-analyses at the patient level of an antiangiogenic
therapy, having evaluated 2748 ramucirumab-treated and 2248
placebo-treated patients. This permits the differentiation of study
drug–related adverse events from toxicities of other anticancer
therapy and the natural history of the disease.
One limitation of this meta-analysis is that despite a population
of approximately 5000 patients, not all rare events may be
observed. However, the 90% CI upper bound for the unobserved
events rate in the current study population is less than 1/1000.
Another (potential) limitation is that most trials reported here rep-
resented unique tumor types (with both REGARD and RAINBOW
being gastric/gastroesophageal junction cancer), but supplemen
tary Table S2, available at Annals of Oncology online, provides a
summary of the incidence rate of a given AE in a given tumor type.
Furthermore, although patients enrolled in these trials met study
inclusion/exclusion criteria, had adequate organ function, and ac-
ceptable concurrent morbidities and medications, they may not re-
flect the general patient population receiving cancer treatment.
Another concern in principle when combining data from multiple
studies is the emergence of the so-called Simpson’s Paradox, in
which a trend appears in different groups of data but disappears or
reverses when these groups are combined [55, 56]. However, this is
specifically a concern when studies are combined in which the ran-
domization ratios differ substantially [57], which was not the case
in the present meta-analysis: four out of the six studies had a com-
mon randomization of 1 : 1, and only the REGARD and ROSE tri-
als, representing about 30% of the total analysis population, had a
ratio of 2 : 1. Similarly, the presence/absence of chemotherapy or
differences in the chemotherapy regime itself between studies is
relevant on its own, particularly in the context of different propor-
tions of patients receiving placebo in different studies.
The safety signal for all therapeutics develops over time. Four
additional phase III global, registrational, placebo-controlled tri-
als with ramucirumab are under way (https://clinicaltrials.gov/).
These ongoing controlled trials will add an additional 1500–2000
patients to the overall ramucirumab-treated population and will
allow further analysis of ramucirumab safety at the patient level.
Conclusions
The importance of our results for clinical practice is that the risk of
developing hypertension, proteinuria, all-grade bleeding, GI per-
foration, IRR, RPLS, and wound-healing delay are consistent with
the reported adverse events associated with the angiogenesis in-
hibitor class. However, we do not observe an increased risk associ-
ated with ramucirumab for developing ATE, VTE, high-grade
bleeding, or high-grade GI bleeding across these trials. Also, the
majority of adverse events are low grade and manageable.
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